Releases - MOBERG DERMA AB

View:
 

Found press releases

 

MOBERG DERMA YEAR–END REPORT 2011

2/9/2012 2:00 AM EST
STRONG REVENUE GROWTH AND SIGNIFICANTLY IMPROVED EARNINGS
FULL YEAR (JAN-DEC 2011)
•    Net sales MSEK 55.9 (8.5)
•    Research and development expenses MSEK 26.8 (19.0)
•    Operating loss MSEK -7.6 (-30.1)
•    Net loss after tax SEK -6.4 (-31.0)
•    Earnings/loss per share SEK -0.82 (-5.08)
•    Operating cash flow per share SEK -0.99 (-4.97)
•    The board proposes that no dividend will be paid for the...

FURTHER STUDIES MAY BE REQUIRED FOR MOB-015

2/9/2012 1:59 AM EST
Moberg Derma AB (OMX: MOB) has analysed data from approximately fifty per cent of the patients in the ongoing open phase II study for MOB-015. Based on the analysis, the company assesses that there is low probability that the final results from the study will be sufficient for out-licensing the project. Further studies will probably be required before continuing to phase III. The ongoing phase II study will be...

MOBERG DERMA STRENGTHENS MANAGEMENT TEAM

1/17/2012 3:30 AM EST
Moberg Derma AB (STO: MOB) has hired Lena Pereswetoff-Morath as Vice President Pharmaceutical Innovation & Development. Lena comes from a similar position at Orexo and has extensive experience in drug development, e.g. from Biolipox and AstraZeneca.
"We have seen strong sales growth for Nalox™ and the additional contracts and product launches create opportunities for international expansion and continued...

MOBERG DERMA TERMINATES COLLABORATION IN CANADA

12/22/2011 9:00 AM EST
Moberg Derma AB (STO: MOB) and Medical Futures Inc. have agreed that the distribution agreement between the parties shall cease, and that cooperation ends. The agreement gave the distributor the exclusive right to market and sell Emtrix® in Canada.
Moberg Derma regains all rights to Emtrix® in Canada. The distributor has the right to sell off its stock for a period.

“Sales in Canada have not met expectations...

MOBERG DERMA AND MENARINI GROUP SIGN AGREEMENT FOR EMTRIX IN ITALY

12/9/2011 2:00 AM EST
Moberg Derma AB (STO: MOB) has entered into a distribution agreement with Menarini Group for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Menarini’s OTC Division is granted exclusive rights to market and sell Emtrix® in Italy under the trademark YouDerm Emtrix®.
“The agreement is part of our international commercialization of Emtrix®. As...

MOBERG DERMA AND MEDA EXTEND LICENSE AGREEMENT

11/30/2011 8:00 AM EST
Moberg Derma AB (publ.) and Meda have entered into an additional license agreement for Nalox™ - Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. The agreement extends Meda's rights to market and sell Nalox™ to Russia, Turkey and several countries in Eastern Europe. Moberg Derma assumes production and supply responsibility.

MOBERG DERMA IS GRANTED MSEK 4 FOR LIMTOP

11/15/2011 6:00 AM EST
Moberg Derma AB (OMX: MOB) has been granted 4 MSEK by Vinnova for the development of Limtop, an innovative formulation for the treatment of actinic keratosis, genital warts and basal cell cancer. The goal of the Vinnova funding is that small and medium-sized enterprises will increase their competitiveness and growth by investing in research and development and thus contribute to growth in Sweden.

MOBERG DERMA INTERIM REPORT JANUARY – SEPTEMBER 2011

10/28/2011 2:30 AM EST
First profitable quarter and licensing agreement with Meda
JANUARY – SEPTEMBER 2011

· Net sales MSEK 35.4 (3.1), an earnings increase of MSEK 32.3
· Research and development expenses MSEK 19.5 (12.9), a cost increase of MSEK 6.5
· Operating loss MSEK -11.4 (-21.2), an improvement of SEK 9.8
· Net loss after tax SEK -10.8 (-22.1), an improvement of MSEK 11.3
· Earnings/loss per share SEK -1.47 (-3.62)
·...

MOBERG DERMA DISCONTINUES PRECLINICAL DEVELOPMENT PROGRAM FOR A-FIZZ

10/27/2011 10:00 AM EST
Moberg Derma AB (OMX: MOB) has decided to discontinue the preclinical program for the drug candidate for treatment of anal fissures - A-Fizz. The decision to discontinue was made since the validating preclinical results did not fulfill the company’s criteria.
“It is a disappointment to discontinue the development program but our product candidates need to meet strict criteria to be approved for continued...

MOBERG DERMA NOMINATION COMMITTEE APPOINTED

10/21/2011 7:00 AM EST
In accordance with the decision taken at Moberg Derma’s Annual General Meeting 2011 the Chairman of the Board has contacted the largest shareholders of the company to appoint a Nomination Committee before the Annual General Meeting 2012.
The appointed Nomination Committee consists of:

Mats Pettersson, Chairman of the Board
Per-Olof Edin, Östersjöstiftelsen
Conny Bogentoft, SIX SIS AG
Oscar Ahlgren, Mohammed Al...

MOBERG DERMA AB


  CONTACT